Two studies based on the KEYNOTE-010 trial data reported the cost-effectiveness of pembrolizumab monotherapy compared with docetaxel as a second-line treatment for patients with NSCLC whose PD-L1 expression was ≥1%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.